Navigation Links
ProEthic Pharmaceuticals Presents Positive Data for PRO-513 at,American Headache Society Meeting

second poster presentation detailed positive secondary endpoint results from the Phase III trial, including results from the 24-hour sustained pain-free response and 24-hour sustained headache response.

In the trial, significantly more patients in the PRO-513 arm achieved a 24-hour sustained pain-free response, than in the placebo arm. Among patients who were pain free at two hours, almost 80% had persistent benefits without headache recurrence or need for rescue medication.. In addition, the number of patients in the PRO-513 arm who were able to perform all daily activities increased eleven-fold from baseline to two hours and over 18 times within 24 hours.

Adverse events in the Phase III trial were comparable between the PRO-513 and placebo arms and were generally mild to moderate in severity. No serious adverse events were reported. The results were similar for the intent-to-treat group and the per protocol population.

"PRO-513 was able to meet all of its co-primary endpoints as well as key secondary endpoints in its Phase III trial," Dr. Richard Lipton stated. "With its ability to rapidly relieve the pain of migraine and the associated symptoms, PRO-513 would represent an important first line treatment option for migraine sufferers were it to be approved."

Carl Whatley, Chairman and CEO of ProEthic Pharmaceuticals, stated, "The findings presented today will serve as the basis for our New Drug Application for PRO-513, which will be filed by the end of the second quarter. The market for migraine therapies is significant, yet filled with a high degree of patient dissatisfaction. If approved, we believe PRO-513 would advance the standard of care in migraine treatment by providing distinct advantages over current therapies in both efficacy and tolerability."

Technology Platform

PRO-513 utilizes ProEthic's patented Dynamic Buffering Technology (DBT), which enhances the absorption of its active ingredient, diclofenac potassium.
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... a stock purchase agreement to acquire 100% of QCR ... based distribution organization. The transaction closed on ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... N.Y. , Nov. 21, 2014  Cardinal Health, ... world,s largest health care services companies, and Henry Schein, ... provider of health care products and services to office-based ... the companies have entered into a long-term strategic agreement ... product offerings to office-based medical practices.  This strategic agreement ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... In the year since a devastating earthquake struck Haiti on ... world have launched and supported projects to help the country ... began, Rotary clubs started a $200,000 initiative to implement cholera ... waterborne disease. Rotary clubs worldwide have contributed more ...
... Cardinal Health plans to release second-quarter financial results for its ... of trading on the New York Stock Exchange. ... Feb. 3 at 8:30 a.m. EST to discuss second-quarter results. ... the Investor page at cardinalhealth.com/investors or dial 857-350-1669 passcode 24786608. ...
Cached Medicine Technology:Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 2Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 3Cardinal Health to Release Second-Quarter Results on Feb. 3 2
(Date:11/23/2014)... 2014 BambooFlooringChina.com , the world’s leader ... strand woven bamboo flooring collection. Now, the business is ... company’s CEO, the promotion is valid until Dec. 20, 2014. ... a smooth and dust-free surface, which makes it very easy ... industry, the company wants to make its website the best ...
(Date:11/22/2014)... Cancer researchers in New York and ... communication tunnels and the growth and spread of mesothelioma. ... on the Surviving Mesothelioma website. , Doctors at ... Minnesota have just released their study on tunneling nanotubes ... cells. They found that mesothelioma cells contain ...
(Date:11/22/2014)... Recently, Locks-Magnetic.com , one of ... promotion of mag locks for glass doors online. In ... on these fresh products. Customers can get more information ... doors are in excellent performance. Customers who want to ... soon as possible. They also can enjoy the ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 “Due to my ... an inventor, from Gurnee, Ill. “While using the ice grip ... and I thought there needed to be a safer way ... the SPIKE BLOCK. , The SPIKE BLOCK offers added safety ... it would help to reduce injuries and damage associated with ...
(Date:11/22/2014)... PA (PRWEB) November 22, 2014 "My ... the pain caused by the machine," said an inventor ... she had to go back a second time because ... invention idea." , She developed the patent-pending MAMO EASY ... breast cancer. The design saves the patient from the ...
Breaking Medicine News(10 mins):Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2
... ... Club, the Endangered Habitats League and SOS Hills will honor "Avatar" ... Outstanding Social Responsibility in Media. "Avatar,s" themes closely mirror the ... residents are facing against Granite Construction, a powerful corporation that wants ...
... ... medical experience. , ... Scottsdale, AZ (PRWEB) March 3, 2010 -- NightHawk Radiology Services, the leading ... named two new physician leaders to its Medical Executive Team (MET), an influential group ...
... , ... ... ... ...
... ... ... ... ...
... forms of Leukaemia have identified a new drug target to ... diseased cells. The research, reported in EMBO Molecular Medicine ... if targeted could prevent diseased cells from developing. The ... Vienna, carried out their research on acute lymphoid leukaemia (ALL) ...
... from injuries to the distal biceps tendon may benefit from ... review article published in the March 2010 issue of the ... (JAAOS). Located in the front of the elbow, the distal ... muscle, and is responsible for two primary motions: , ...
Cached Medicine News:Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 2Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 3Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 4Health News:NightHawk Radiology Services Expands Its Medical Executive Team 2Health News:NightHawk Radiology Services Expands Its Medical Executive Team 3Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 2Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 3Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 4Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 2Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 3Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 4Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 5Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 6Health News:Targeting leukemia cell's gene 'addiction' presents new strategy for treatment 2Health News:Battling a biceps injury 2Health News:Battling a biceps injury 3
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
This optimal design addresses low-cost, simple, non-invasive ankle distraction....
Medicine Products: